

## Title Page

# **The Novel, Clinical Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease**

### **Authors:**

Glenn A. Reinhart, Paul C. Harrison, Kathleen Lincoln, Hongxing Chen, Peng Sun, Jon Hill, Hu Sheng Qian, Mark C. McHugh, Holly Clifford, Khing Jow Ng, Hong Wang, Danielle Fowler, Kristina Gueneva-Boucheva, Jehrod B. Brennen, Todd Bosanac, Diane Wong, Ryan M. Fryer, Chris Sarko, Carine M. Boustany-Kari, Steven S. Pullen

### **Origin:**

**Departments of Cardiometabolic Diseases Research (G.A.R, P.C.H, K.L., H.C., P.S., H.Q., M.C.M., H.C., J.N., H.W., D.F., C.M.B.-K., S.S.P.), Small Molecule Discovery Research (K.G.-B., J.B.B., T.B., D.W., C.S.), Global Computational Biology and Data Sciences (J.H.), Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.**

## Running Title Page

**Kidney protective effects of BI 685509**

**Corresponding Author:**

**Steven Pullen**

**900 Ridgebury Road, PO Box 368**

**Ridgefield, CT 06877**

steven.pullen@boehringer-ingenelheim.com

**Number of text pages – 22**

**Number of tables - 1**

**Number of figures 10**

**Number of references - 25**

**Number of words in abstract - 247**

**Number of words in introduction - 748**

**Number of words in discussion – 1489**

**Non-standard abbreviations:**

$\alpha$ -SMA	alpha smooth muscle actin
ACE	angiotensin converting enzyme
ARB	angiotensin receptor blocker
bpm	beats per minute
BSA	bovine serum albumin
cGMP	cyclic guanosine monophosphate
CKD	chronic kidney disease
DKD	diabetic kidney disease
EC50	half maximal effective concentration
eNOS	endothelial nitric oxide synthase
ESRD	end stage renal disease
FBS	fetal bovine serum
GTP	guanosine-5'-triphosphate
H&E	hematoxylin and eosin
HR	heart rate
HTRF	Homogenous Time Resolved Fluorescence

IBMS	3-Isobuytl-1-methylxanthine
KIM-1	kidney injury molecule 1
LC/MS/MS	liquid chromatography/mass spectrometry/mass spectrometry`
MAP	mean arterial pressure
mmHg	millimeters mercury
NBS	non-binding surface
NGS	next generation sequencing
NO	nitric oxide
ODQ	1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1one
PAM	periodic acid methenamine
PBS	phosphate buffered saline
PRP	platelet-rich plasma
sGC	soluble guanylate cyclase
T2DM	type 2 diabetes mellitus
UPE	urinary protein excretion

### **Section assignment – Drug Discovery and Translational Medicine**

## Abstract

Activation of soluble guanylate cyclase (sGC) to restore cyclic guanosine monophosphate (cGMP) and improve functionality of nitric oxide (NO) pathways impaired by oxidative stress is a potential treatment for diabetic and chronic kidney disease. We report the pharmacology of BI 685509, a novel, orally active small molecule sGC activator with disease modifying potential. BI 685509 and human sGC  $\alpha 1/\beta 1$  heterodimer containing a reduced heme group, produced concentration-dependent increases in cGMP that were elevated modestly by NO whereas heme-free sGC and BI 685509 greatly enhanced cGMP with no effect of NO. BI 685509 increased cGMP in human and rat platelet-rich plasma treated with the heme-oxidant ODO; respective  $EC_{50}$  values were 467 nM and 304 nM. In conscious telemetry-instrumented rats, BI 685509 did not effect mean arterial pressure (MAP) or heart rate (HR) at 3 and 10 mg/kg (p.o.) whereas 30 mg/kg decreased MAP and increased HR. Ten-days of BI 685509 at supratherapeutic doses (60 or 100 mg/kg po, qd) attenuated MAP and HR responses to a single 100 mg/kg challenge. In the ZSF1 rat model, BI 685509 (1, 3, 10, 30 mg/kg/day qd) co-administered with enalapril (3 mg/kg/day) dose-dependently reduced proteinuria and incidence of glomerular sclerosis; MAP was modestly reduced at the higher doses vs. enalapril. In the 7-day rat UUO model, BI 685509 dose-dependently reduced tubulointerstitial fibrosis ( $p < 0.05$  at 30 mg/kg). In conclusion, BI 685509 is a potent, orally bioavailable sGC activator with clear renal protection and anti-fibrotic activity in preclinical models of kidney injury and disease.

**SIGNIFICANCE STATEMENT:** BI 685509 is a novel small sGC molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. In BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of DKD, and reduced tubulointerstitial fibrosis in a rat 7-Day UUO model. Thus, BI 685509 is a promising new therapeutic agent and is currently in Phase II clinical trials for CKD and DKD.

## Introduction

Soluble guanylate cyclase (sGC) serves as a receptor for nitric oxide (NO) and is the key signal-transduction enzyme in the NO-cyclic guanosine monophosphate (cGMP) pathway. Diminished responsiveness of the NO-cGMP pathway has been implicated in the pathogenesis of cardiovascular and kidney diseases, conditions associated with elevated oxidative stress. Thus, drug discovery research efforts have centered on improvement of sGC function using small molecule modulators for the treatment of human diseases including chronic kidney disease (CKD).

sGC is a heterodimeric protein complex comprised of  $\alpha$ - and  $\beta$ - subunits with a heme prosthetic group located in the  $\beta$ -subunit. NO, a transient and locally acting signaling molecule, exerts its action by binding to the heme prosthetic group to induce a conformational change which stabilizes the protein in a catalytically active state, thus enabling conversion of guanosine-5'-triphosphate (GTP) to cGMP. cGMP modulates the activity of multiple downstream targets including protein kinase G, cyclic nucleotide-gated ion channels, and phosphodiesterases (Stasch et al., 2001).

Conditions of persistent oxidative stress occur in patients with diabetes, cardiovascular diseases and chronic / diabetic kidney disease and are associated with increased levels of reactive oxygen species (ROS). ROS can oxidize the heme iron of sGC, converting  $\text{Fe}^{2+}$  to  $\text{Fe}^{3+}$  which destabilizes the heme group and can lead to its loss, and react directly with NO, thereby decreasing its abundance. Thus, elevated oxidative stress induces deficiencies of NO and cGMP signaling through a variety of mechanisms (Gillis et al., 2018).

Two classes of compounds termed stimulators and activators have been identified which restore cGMP production by sGC through differing mechanisms. The sGC stimulators enhance cGMP

generation in the absence and presence of NO when the iron within the heme prosthetic group is in a reduced state (Stasch et al., 2001). In contrast, sGC activators increase cGMP synthesis independent of NO through interactions in the heme binding site which stabilize the enzyme in a catalytically active conformation (Stasch et al., 2002). Oxidation or loss of the heme prosthetic group renders the enzyme non-functional and non-responsive to sGC stimulators (Stasch et al., 2001) whereas sGC activators are optimally active under these conditions since binding requires displacement of the heme group (Stasch et al., 2006). These mechanisms are nicely depicted in a review by Stasch et al. 2015.

Diabetic kidney disease (DKD) is the leading cause of kidney failure or end-stage renal disease (ESRD) in the developed world (Koye et al., 2018, Tuttle et al., 2014). Until recently, approved treatment options for DKD have been limited to the angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). While ACEi/ARB were the standard of care for two decades, many treated patients continued to progress to ESRD (Brenner 2001, Lewis 1993, Lewis 2001). While the recent approval of SGLT2 inhibitors for treatment of CKD and/or DKD expand the previous limited standard of care, considerable unmet medical need persists, and additional therapies are required for disease management.

The progression of DKD has been linked to impaired endothelial function. Evidence to support the role of endothelial dysfunction in contributing to DKD is provided by polymorphisms in eNOS which lead to reduced enzyme activity, increased risk of disease (Dellamea et al., 2014) and an association of elevated plasma levels of endothelial dysfunction biomarkers with disease progression (Persson et al., 2008, Lajer et al., 2008, Hanai et al., 2009, Shibata et al., 2009). A potential new approach to the treatment of DKD would be to directly augment sGC activity to



restore signaling within this pathway and in turn bypass defects associated with reduced NO production by eNOS.

Previously, we demonstrated that sGC activator monotherapy reduced renal injury in the ZSF1 model of DKD (Boustany-Kari et al., 2016). We hypothesized that sGC activator treatment would provide added therapeutic benefit in the ZSF1 model when co-administered with a clinically relevant dose of enalapril, an ACEi representing standard of care. The present report highlights the pharmacology of BI 685509, a novel, potent and selective clinical stage sGC activator, currently in Phase II for CKD (NCT04736628) and DKD (NCT04750577). In addition to presenting the relevant in vitro pharmacology, we demonstrate the ability of BI 685509 to attenuate disease progression in the ZSF1 rat model when co-administered enalapril, thereby demonstrating the potential of BI 685509 to deliver therapeutic benefit to patients receiving standard therapy of ACEi/ARB. Finally, since tubulointerstitial fibrosis is a known predictor of progression of CKD, we also demonstrate the anti-fibrotic effect of BI 685509 in the rat unilateral ureteral obstruction (UUO) model, a rapid preclinical model of tubulointerstitial fibrosis.

## Materials and Methods

All in vivo studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health, and under an IACUC approved study protocol at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 or in accordance with the German and European Animal Welfare Act and authorized by the Regierungspräsidium Tübingen as the responsible local German authority.

Methods used to perform the primary pharmacology studies are detailed below whereas methods for supporting assays and models are detailed in the Supplemental Information document available online. The supplemental information includes a detailed description of materials and methods relevant to rat cardiovascular (telemetry) studies, pharmacokinetic studies including PK/PD modeling, tissue collection and processing including assessment of renal histopathology, and Next Generation Sequencing.

### sGC activity assay

Recombinant reduced and heme-free human sGC were generated as previously described (Nedvetsky et al., 2002). Enzyme (0.2 nM reduced or 0.1 nM heme-free), 1 mM DETA NONate (when included), and compounds were preincubated at room temperature for 10 min in reaction buffer (50 mM MOPS, pH 6.8, 5 mM MgCl<sub>2</sub>, 50 mM NaCl, 0.2 mM TCEP, 1 mM IBMX, 0.1% BSA). GTP at a final concentration of 50 μM was added to initiate the reaction for 30 minutes at 37°C. Cyclic GMP was quantified in a competitive immunoassay using homogenous time-resolved fluorescence (HTRF) following the manufacturer instructions (Cisbio, Bedford, MA).

### Human PRP Assay

Human forearm blood was drawn aseptically under informed consent by veni-puncture using a 21-gauge needle from healthy human volunteers. Blood was collected into Vacutainer glass tubes containing 3.2% sodium citrate, poured into 50 mL conical centrifuge tubes, and centrifuged for 16 minutes at 200 g at room temperature. The upper platelet-rich plasma layer was collected, and 35  $\mu$ L was transferred to a 96 well half area plate and incubated at 37°C for 10 minutes. 35  $\mu$ L of BI 685509 was added and incubated at 37°C for 10 minutes. In a 384 well low volume black round bottom polystyrene NBS microplate, 10  $\mu$ L PRP incubation reaction solution, 5  $\mu$ L of cGMP-XL665 conjugate, and 5  $\mu$ L anti-cGMP cryptate conjugate were combined and incubated at room temperature for 60 minutes in the dark. Cyclic GMP concentration was quantified in a competitive immunoassay using HTRF.

## **ZSF1 model of diabetic kidney disease**

### **Animals**

Sixty male ZSF1 obese rats were obtained from Charles River Labs (Kingston, NY) following surgical implantation of telemetry transmitters (Data Sciences International, Inc., PA11TA-C40) in the abdominal artery to allow for continuous monitoring of MAP and HR. Rats were acclimated to metabolism cages (Lab Products, Inc., Seaford, DE) for 11 days prior to baseline collections and remained in these cages throughout the study to allow for weekly collection of urine. Two baseline urine measurements were collected. The first baseline (pretest) was collected over 8 days (14-15 weeks of age) and the rats were subsequently separated into two groups based on urinary protein excretion (UPE), MAP, HR, and body weight. Animals assigned to treatment (n=50 in total) received enalapril (3 mg/kg/day in 1% Pluronic F127/DI water, 5 mL/kg p.o.) lead-in, prior to randomization into treatment groups, while the untreated

animals (n=10) received vehicle alone (1% Pluronic F127/DI water). Thereafter, a second baseline used to assign animals to the study groups was collected during the enalapril lead-in phase of the study (9 days). The animals assigned to treatment (16-17 weeks of age) were next assigned into specific groups based on their average second baseline UPE, MAP, HR and body weight; treatment groups received either enalapril (3 mg/kg/day, p.o., n=10) or one of four doses of BI 685509 (1, 3, 10 or 30 mg/kg/day) in combination with enalapril (3 mg/kg/day, p.o.; n=10/group).

A general study protocol for ZSF1 (and UUO) studies is shown in Suppl. Fig. 1. All oral dosing was performed at a volume of 5 mL/kg. Throughout the study, rats had ad lib access to diet (Purina Formulab 5008, WF Fisher & Son, Inc., Somerville, NJ). Rats were subsequently monitored for 10 weeks during which body weight was recorded once per week, and food intake and water intake thrice weekly. Urine was collected chilled once weekly over a 24-hour period for measurement of protein contents. Blood samples were collected at baseline, following 1, 4 and 7 weeks of treatment, and at study termination (week 10) for pharmacokinetic, clinical chemistry, plasma glucose and HbA1c measurements. Hemodynamic parameters were recorded intermittently (30 seconds of continuous data every 10 minutes) and weekly 24-hour averages were calculated. At study end, rats were sacrificed under isoflurane anesthesia by exsanguination through cardiac puncture and kidneys were collected for histological analysis.

### **Unilateral Ureteral Obstruction (UUO) Model**

Forty-eight 8-week-old male SD rats from Taconic Bioscience were randomized into 4 groups: sham group of 8 rats with sham UUO surgery, and 10 rats of each group for the remaining three UUO groups. UUO surgery is similar as described (Nagle, et al., 1973) under isoflurane-induced

anesthesia using aseptic techniques. A midline abdominal incision was made to access the kidney, the left ureter was occluded and ligated at the level of the lower renal pole to induce irreversible UUU. The incision was closed, and the animals were allowed to recover under observation. During the study, all animals were orally dosed with either vehicle (1% Pluronic F127/DI water, 5 mL/kg) or test article BI 685509 at 10 or 30 mg/kg/day. Seven days post-surgery, animals were sacrificed, and the left kidney collected for assessment of tubulointerstitial fibrosis (TIF) and next generation sequencing (NGS) data generation. Obstructed kidneys were sectioned transversally to generate a 3-5 mm slice in thickness, placed into a histocassette and stored in 10% formalin for a minimum of 24 hrs. After standard histological processing, 4  $\mu$ m thick paraffin embedded tissue sections were placed on glass slides for SRM staining and fibrosis analysis. For NGS analysis sample generation, 5-10 mg of cortical tissue from the obstructed kidney was collected and placed in RNALater overnight, then stored at -80°C prior to RNA extraction, QC, and NGS data generation. Experimental animals had free access to food and water during the study.

### **Statistical Analysis**

Data collected repetitively over time were analyzed using a 2-way ANOVA with repeated measures and a Bonferroni post-hoc analysis. Data obtained through single measurements (histological endpoints) were analyzed using a 1-way ANOVA with Tukey's post-hoc analysis. Data were plotted as mean  $\pm$  SEM with a P value  $\leq 0.05$  considered statistically significant. Statistical analysis was performed using GraphPad Prism Version 6.01 (GraphPad Software, Inc., La Jolla, CA).

## Results

**In vitro profile of a novel sGC activator:** sGC enzyme exists in different biologically relevant forms, each characterized by the status of the iron heme prosthetic group: the native form of sGC functions as the biological ‘receptor’ for NO and is the heme-containing, reduced form.

Additional forms of sGC are the oxidized and heme-free that no longer bind NO and are catalytically inactive. Meanwhile, sGC activators and stimulators are differentiated by the specific cGMP response profile each generates. sGC stimulators are heme-dependent with regards to inducing cGMP generation while sGC activators are heme-independent; also, sGC activators can potently augment cGMP production in the absence of NO, especially when the sGC enzyme is heme-free (Stasch et al. 2006). Using human sGC  $\alpha 1/\beta 1$  heterodimer containing a reduced heme group, BI 685509 (Fig. 1) produced concentration-dependent increases in cGMP that were elevated modestly in the presence of NO (Fig. 2A). Moreover, heme-free sGC tested with increasing concentrations of BI 685509 displayed greatly enhanced cGMP generation, an effect that was not altered by the presence of NO, consistent with the profile of an sGC activator (Fig. 2A).

In contrast, pralicigat, an sGC stimulator (Tobin et al., 2018), had no effect on heme-free sGC activity in the presence or absence of NO. However, under conditions of a reduced sGC heme group, pralicigat produced a concentration-dependent increase in cGMP, a response that was greatly shifted leftward and upward by NO (Fig. 2B) and is consistent with that of an sGC stimulator.

In further experiments, the ability of recombinant sGC  $\alpha 1/\beta 1$ , heme-free enzyme to be activated by BI 685509 was tested for different animal species and using the human  $\alpha 2/\beta 1$  enzyme. BI

685509 increased cGMP production with an EC<sub>50</sub> of 9.29, 3.52, 4.69, 8.65, and 5.54 nM against the mouse, rat, dog, cynomolgus monkey, and human  $\alpha$ 2/ $\beta$ 1 enzyme, respectively, compared with an EC<sub>50</sub> of 6.81 nM against the human  $\alpha$ 1/ $\beta$ 1 enzyme.

BI 685509 increased cGMP levels in human PRP treated with the heme-oxidant 1H-[1,2,4] Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) with an EC<sub>50</sub> of 467 nM (Fig. 3). In rat PRP in which sGC was similarly oxidized, BI 685509 increased cGMP with an EC<sub>50</sub> of 304 nM demonstrating good congruency across species in a more complex system expected to better mimic the in vivo condition by accounting for plasma protein binding.

**Pharmacokinetic profile - Mouse and Rat PK properties:** Following oral gavage dosing in mice or rats, BI 685509 was rapidly absorbed achieving maximal plasma concentration at the first collection timepoint of 0.25 hr in both species (Suppl. Tables 1 and 2). After i.v. administration in rats, BI 685509 displayed a low volume of distribution at steady state (V<sub>ss</sub>) of 1.05 L/kg and moderate clearance (32.1 mL/min/kg) leading to short half-life (~1.8 hr) and moderate bioavailability of ~60%.

**Telemetry Rat Blood Pressure and Heart Rate Profile - Single Dose Study:** During the 24-hr baseline period (values calculated every 10 min), MAP and HR values were similar across groups. BI 685509 at 3 or 10 mg/kg elicited no consistent reductions in MAP and no significant increase in HR compared to vehicle controls although HR trended upward in response to treatment. In the 30 mg/kg dose group (and within 40 minutes post-dose) MAP decreased significantly to 12-25 mmHg below baseline while HR increased to 17% above baseline (Fig. 4A and B). While blood samples were not collected during the initial 8-hour observation period to avoid artifactual changes in MAP and HR, exposures from satellite animals (n=4-5/group)

exhibited  $C_{\max}$  values of 60, 410, and 830 nM, respectively for the doses used. These data suggest that a  $C_{\max}$  as high as 410 nM BI 685509 exerted no significant, acute effects on BP or HR. In addition, respective drug concentrations in telemetry animals at 8 hrs post-dose were  $24 \pm 5.9$  nM,  $41 \pm 5.8$  nM and  $201 \pm 37.2$  nM, concentrations consistent with the  $C_{\max}$  values observed in the satellite animals.

**Telemetry Rat Blood Pressure and Heart Rate Profile - 10 Day Repeat Dose Study:** On Day 1, BI 685509 at 60 or 100 mg/kg, p.o., produced the expected dose-dependent decreases in MAP and corresponding elevations in HR, responses that were generally attenuated during the subsequent 10 days of successive dosing (Fig. 4C). On the last day of the study (Day 11), animals were challenged with a hypotensive dose of BI 685509 (100 mg/kg) to assess attenuation of the blood pressure response after repeated dosing. Reductions in MAP elicited by the 100 mg/kg challenge dose were not different in the Vehicle animals compared to Day 1 (*t*-test). In contrast, acute reductions in MAP produced by the 100 mg/kg challenge of BI 685509 were significantly attenuated following 10-days of repeat dosing in the 60 and 100 mg/kg treatment groups. Similarly, acute increases in HR produced by the 100 mg/kg BI 685509 challenge were significantly attenuated following repeat dosing of BI 685509 compared to Vehicle (Fig. 4C). Collectively, these data demonstrate that the initial, acute depressor and HR responses to high doses of BI 685509 attenuate markedly in response to repeated dosing, an effect that becomes apparent as early as the second day of treatment.

**Effect of BI 685509 in the rat ZSF1 model of diabetic kidney disease.** Mean plasma concentrations of BI 685509 across weeks 1, 4, 7, and 10 in animals treated with 1, 3, 10 or 30 mg/kg/day, p.o. in combination with enalapril (3 mg/kg/day) are shown in Suppl. Fig. 3. At 1 hour post dose, mean plasma concentrations of BI 685509 were  $226 \pm 122$ ,  $485 \pm 161$ ,  $2210 \pm$



616,  $1610 \pm 340$  nM. Exposure for the 10 and 30 mg/kg/day doses were roughly similar across the measured time points of 1, 6, and 24 hours (although the 24 hr values showed dose dependence) suggesting that rate limited absorption may be occurring at doses  $>10$  mg/kg/day. Meanwhile, plasma concentrations of enalaprilat, the active metabolite of enalapril, were comparable across the different treatment groups (Suppl. Fig. 3).

Body weight, food- and water intake were not significantly different between study groups (Suppl. Fig. 4) at baseline or during BI 685509 treatment + enalapril or enalapril alone throughout the 10-week observation period.

HbA1c levels and non-fasting plasma glucose following BI 685509 + enalapril were not significantly different from either vehicle or enalapril [change from baseline HbA1c%:  $1.0 \pm 0.3$ ,  $1.2 \pm 0.5$ ,  $1.4 \pm 0.5$ ,  $1.4 \pm 0.4$ ,  $1.1 \pm 0.5$ ,  $0.7 \pm 0.7$ , and change from baseline plasma glucose:  $10.4 \pm 24.1$ ,  $116.1 \pm 20.8$ ,  $75.6 \pm 34.9$ ,  $122.9 \pm 23.3$ ,  $101.2 \pm 37.5$ ,  $140.8 \pm 33.5$  mg/dL for vehicle, enalapril and BI 685509 at 1, 3, 10 and 30 mg/kg/day, respectively, in combination with enalapril;  $P>0.05$ ].

At baseline (following enalapril lead-in dosing), there was no significant difference in MAP or HR between the BI 685509 + enalapril combinations and enalapril alone study groups [MAP:  $114 \pm 2$ ,  $108 \pm 1$ ,  $106 \pm 1$ ,  $111 \pm 2$ ,  $110 \pm 2$ , and  $106 \pm 2$  mmHg, and HR:  $284 \pm 4$ ,  $283 \pm 4$ ,  $279 \pm 2$ ,  $294 \pm 4$ ,  $290 \pm 5$ , and  $285 \pm 2$  bpm for vehicle, enalapril and BI 685509 at 1, 3, 10 and 30 mg/kg/d, respectively, in combination with enalapril;  $P>0.05$ ]. BI 685509 at 30 mg/kg/day + enalapril (3 mg/kg/day) significantly reduced MAP compared to both vehicle and enalapril alone from study week 1 onward (Fig. 5A). Lower doses of BI 685509 + enalapril significantly reduced MAP at 10, 3 and 1 mg/kg/day beginning on weeks 2, 3 and 4, respectively, vs vehicle,

and beginning on week 2 at 10 mg/kg/day compared to enalapril alone. In comparison, enalapril alone only significantly reduced MAP versus vehicle from week 7 onward.

HR decreased steadily over time in all study groups, including vehicle (Fig. 5B), and the magnitude of decline was less pronounced as the dose of BI 685509 increased and MAP reductions were more prominent. BI 685509 at 30 and 10 mg/kg/d + enalapril significantly increased HR beginning on weeks 1 and 9, respectively, compared to enalapril alone, while BI 685509 30 mg/kg/d + enalapril exhibited significant increases in HR on weeks 1, 2, 3 and 8 compared to vehicle. There was no significant effect of BI 685509 at 1, 3 or 10 mg/kg/d in combination with enalapril or enalapril alone on HR compared to vehicle.

There was no significant difference in urinary protein excretion (UPE) at baseline between study groups [UPE:  $156 \pm 18$ ,  $144 \pm 18$ ,  $141 \pm 10$ ,  $127 \pm 14$ ,  $125 \pm 20$ , and  $130 \pm 10$  mg/day for vehicle, enalapril, and BI 685509 at 1, 3, 10 and 30 mg/kg/day in combination with enalapril, respectively;  $P > 0.05$ ]. Administration of BI 685509 at 30 and 10 mg/kg/d + enalapril, significantly reduced UPE levels from weeks 4 and 8 onward, respectively, compared to enalapril alone (Fig. 5C). BI 685509 + enalapril, showed significant reductions in UPE at 30, 10, 3 and 1 mg/kg/day beginning on weeks 3, 3, 3 and 7, respectively, compared to vehicle. Enalapril (3 mg/kg/day) significantly reduced UPE levels versus vehicle from week 7 onwards.

To determine BI 685509 in vivo potency in reducing UPE, individual mean plasma concentrations were correlated with an overall UPE change from baseline (AUC) utilizing an inhibitory effect  $I_{\max}$  model (Fig. 6A and B). An  $IC_{50}$  of 213 nM  $C_{\max}$  (63.4% CV) and 1210 nM\*hr (63.5% CV) AUC was predicted to reduce UPE by 50% on top of enalapril, a value that is close to that of the rat PRP  $EC_{50}$  (304 nM).

Kidney weight to body weight ratios for left and right kidneys were not different after 10 weeks of BI 685509 + enalapril or enalapril alone. The average left kidney weight/body weight ratios were: vehicle,  $0.415 \pm 0.015$ ; enalapril,  $0.413 \pm 0.034$ ; BI 685509 in combination with enalapril,  $0.402 \pm 0.012$ ,  $0.392 \pm 0.017$ ,  $0.376 \pm 0.018$  and  $0.382 \pm 0.017$  at 1, 3, 10 and 30 mg/kg/day, respectively. The average right kidney weight/body weight ratios were: vehicle,  $0.416 \pm 0.021$ ; enalapril,  $0.405 \pm 0.016$ ; BI 685509 in combination with enalapril,  $0.389 \pm 0.009$ ,  $0.381 \pm 0.014$ ,  $0.380 \pm 0.016$  and  $0.382 \pm 0.017$  at 1, 3, 10 and 30 mg/kg/day, respectively.

Incidence of glomerulosclerosis was slightly reduced by enalapril (3 mg/kg/day;  $7.4\% \pm 1.8\%$  decrease versus vehicle;  $P > 0.05$ ), without achieving statistical significance. In contrast, BI 685509 + enalapril, dose-dependently reduced the incidence of glomerulosclerosis with reductions achieving statistical significance in both the 10 and 30 mg/kg/d groups compared to both enalapril alone and vehicle (Figs. 7 and 8). Mean reductions in glomerular sclerosis incidence were similar for the 10 and 30 mg/kg BI 685509 + enalapril groups.

A limitation of the rat ZSF1 model is that lack of development of TIF and other features of advanced kidney disease including a reduction in glomerular filtration rate. To ascertain whether BI 685509 treatment modulated early markers of disease mechanisms including fibrosis, tubular injury, and inflammation,  $\alpha$ -SMA, KIM-1, and ED-1, respectively, were quantified in kidney cortex tissue by immunohistochemistry. BI 685509 + enalapril, significantly reduced  $\alpha$ -SMA expression at all doses tested compared with vehicle and at doses of 3, 10 and 30 mg/kg/day compared with enalapril alone (Table 1). Enalapril (3 mg/kg/day) modestly and significantly reduced  $\alpha$ -SMA expression. BI 685509 + enalapril, significantly reduced KIM-1 expression at 3 and 10 mg/kg/day compared with vehicle (Table 1). Enalapril alone did not result in a significant reduction in KIM-1 expression ( $P > 0.05$ ). Numerical reductions in ED-1 expression

not achieving statistical significance were observed in BI 685509 + enalapril and enalapril alone groups (Table 1). In addition, urinary KIM1 and NGAL were not statistically different compared with enalapril across the BI 685509 treatment groups.

**Effect of BI 685509 in the rat UUO model of tubulointerstitial fibrosis:** With TIF reported as percentage of fibrotic (Sirius Red stained) area, seven days of UUO induced a ~3.5-fold fibrosis increase in Vehicle UUO group compared to sham (\*\* P<0.01, Fig. 9). BI 685509 dose dependently decreased TIF in comparison to Vehicle; the 10 mg/kg dose reduced TIF to 10.7%± 0.7% below sham a response that did not achieve statistical significance, while the 30 mg/kg dose significantly reduced TIF to values 17.9% ± 0.8% below sham (\*P<0.05) vs. Vehicle.

In NGS analysis of tissue from UUO kidneys, principal component analysis showed the samples to be well-grouped by experimental condition, with the sham surgery segregating from the UUO treatment in principal component 1, and the BI 685509-treated animals separating from vehicle treatment in principal component 2 (Fig. 10A). The two dose groups did not separate within the principal components and additionally had a high degree of concordance in their differentially expressed genes when compared to the vehicle-treated group, indicating qualitatively similar pharmacodynamic effects (Suppl. Fig. 5). These two doses were combined for later analyses. The differential gene expression analysis on the RNA samples from the UUO model yielded 231 genes when comparing the Vehicle and combined BI 685509 treated groups (Fig. 10B and Suppl. Table 3). This signature included downregulation of four genes associated with urea transport (Slc14a1, Slc14a2, Upk3a, and Aqp3) with BI 685509 treatment (Suppl. Fig. 6). Additional analysis showed downregulation by BI 685509 of many key genes associated with the development of extracellular matrix which had increased in the Vehicle group, consistent with the observed effect on histology (Suppl. Fig. 7). Key podocyte markers, including Nphs1, Nphs2,

and Podxl, showed reduced expression to a lesser degree in the BI 685509 treated animals compared with the Vehicle group (Suppl. Fig. 8).

## Discussion

We describe a novel, clinical stage sGC activator, BI 685509, which demonstrates renoprotective effects in two models of kidney disease. Our in vitro studies defined BI 685509 as a potent activator of heme-free human sGC enzyme, producing concentration dependent increases in cGMP that were independent of NO. BI 685509 demonstrates low nM potency for sGC  $\alpha 1\beta 1$  activation across multiple mammalian species and the human  $\alpha 2/\beta 1$  enzyme. As expected, the in vitro profile of BI 685509 contrasts with that of an sGC stimulator such as praliciguat (Tobin et al., 2018), which displayed a clear lack of activity in the absence of heme.

In human PRP, a more complex in vitro model with greater in vivo relevance compared to the molecular assays due to plasma protein binding, BI 685509 increased cGMP in a concentration dependent fashion. BI 685509 increased cGMP in human and rat PRP with an  $EC_{50}$  of 370 nM and 304 nM, respectively. In the ZSF1 rat, co-administration with enalapril producing BI 685509 exposures that exceeded the PRP  $EC_{50}$  by ~3-4 fold delivered significant reductions in UPE and reduced the incidence of glomerular sclerosis when compared to the effects of enalapril alone. Moreover, when the ZSF1 UPE and individual mean plasma concentrations of BI 685509 from weeks 1, 4, 7, and 10 were correlated in an inhibitory effect  $I_{max}$  model, an  $IC_{50}$  of 213 nM was observed, a concentration similar to the rat PRP  $EC_{50}$  of 304 nM. These data, in addition to demonstrating pharmacologic congruency between the PRP assay and the ZSF1 disease model suggest the potential for BI 685509 to exert disease modifying effects in patients with persistent oxidative stress, such as CKD/DKD patients, at nanomolar exposures, a hypothesis to be tested in current clinical trials.

In addition to being a selective and potent sGC activator, BI 685509 is orally bioavailable with rapid absorption in mouse and rat and, at a dose of 30 mg/kg, elicits transient reductions in blood pressure and concomitant elevations in heart rate in the conscious rats. These acute blood pressure reductions were associated with a  $C_{\max}$  of 830 nM, a value well above the rat PRP of 304 nM whereas a  $C_{\max}$  of 410 nM had no effect. Given that acute reductions in blood pressure are not desirable at clinically relevant doses, we assessed whether repeated administration of suprathreshold, depressor doses of BI 685509 would moderate any blood pressure changes. Our results demonstrate a clear attenuation of acute hemodynamic responses in the normal SD rat following 10-day, repeat oral administration of suprathreshold doses of BI 685509, a response that could not be assessed definitively in the ZSF1 study. In total, these results suggest that acute blood pressure responses are unlikely to increase over time and importantly, that dose titration may be an effective means to minimize risk of blood pressure excursions in patients.

We previously demonstrated that our earlier sGC activator BI 703704, when administered as a monotherapy, inhibited proteinuria and the incidence of glomerular sclerosis in the ZSF1 model of DKD and provided more robust renal protection compared to a clinically relevant dose of enalapril (Boustany-Kari et al., 2016). Here we investigated the ability of BI 685509 to modulate disease progression in the ZSF1 rat when administered on top of the same dose of enalapril, reflecting the fact that ACEi/ARB have been the standard of care (and only approved drug classes) for the treatment of patients with DKD for nearly two decades. Oral administration of BI 685509 on top of an efficacious dose of enalapril was highly effective in preventing progression of DKD in the ZSF1 rat model at doses that produced little to modest reductions in MAP compared to enalapril alone. Treatment with BI 685509 + enalapril for 10 weeks at 3, 10, and 30 mg/kg produced dose dependent, statistically significant decreases in UPE much earlier in

the treatment period (Week 3) than enalapril alone (Week 3 vs Week 7, respectively). Also, onset of reductions in UPE at Week 1 preceded modest decrements in MAP in groups in which MAP was diminished, a response that typically did not reach steady state until Week 5. These temporal differences suggest an early effect on glomerular filtration dynamics independent of subsequent reductions in systemic MAP. The relevance of these observations is two-fold: they suggest a more rapid onset of reduced proteinuria compared to enalapril alone as well as an additive effect of BI 685509 when co-administered with an effective dose of enalapril. Finally, these data suggest that the sGC activator BI 685509 should not impede the renal benefits of ACEi/ARB therapy in DKD patients. These points are important as BI 685509 Phase 2 clinical trials are being conducted in CKD and DKD patients on a stable dose of ACEi/ARB.

Glomerulosclerosis is a hallmark of DKD, and severity of glomerular lesions has been associated with disease progression and doubling of serum creatinine in type 2 diabetic patients with biopsy-proven DKD (An et al., 2015). Oral administration of BI 685509 + enalapril produced dose dependent decreases in the incidence of glomerular sclerosis in ZSF1 rats whereas reductions induced by enalapril alone were not statistically significant. To our knowledge, this is the first report of an sGC activator co-administered with a clinically relevant dose of enalapril or equivalent antagonist of the renin-angiotensin system in a rodent model of DKD, and also the first observation of reduced pathologic remodeling of glomerular structure under study conditions that more closely approximate a relevant clinical scenario. Viewed collectively, these observations suggest the potential for BI 685509 to demonstrate clinical efficacy on top of ACEis/ARBs, a long-standing standard of care for DKD and CKD patients.

The properties of another advanced sGC activator, runcaciguat, have recently been described (Hahn et al., 2021) including demonstration of cardio- and renoprotective effects in several



preclinical models of hypertensive and metabolic cardiorenal disease (Benardeau et al., 2021). Notably, chronic administration of runcaciguat to the Zucker diabetic fatty rat, a metabolic disease model displaying modest kidney pathology compared to the ZSF1 rat, attenuated proteinuria and biomarkers of kidney damage while inducing slight reductions in kidney damage parameters at doses associated with little to no effect on systolic blood pressure (tail cuff; Benardeau et al., 2021).

Tubulointerstitial fibrosis (TIF) has been increasingly recognized as another key hallmark of CKD and as the best predictor of kidney survival and ESRD (Nath et al., 1992; Gewin, 2018). TIF is a focal fibrotic renal event that is distinct from glomerulosclerosis and driven by sequelae downstream to tubular injury.

The ability of BI 685509 to reduce UUO-induced TIF in the present study is consistent with published studies of sGC stimulators in UUO and other models of kidney fibrosis (Stasch et al., 2015) and further demonstrates the potential clinical importance of sGC activators such as BI 685509 in the prevention of progression of DKD/CKD in humans. Consistent with reduced fibrogenesis, the expression of a subset of extracellular matrix genes was significantly induced in the UUO model and inhibited with BI 685509 treatment (Suppl. Fig. 7). This includes several collagens such as *Coll1a1* which is reduced by treatment with BI 685509 and also has a strong correlation with morphometric measurements of TIF (Suppl. Fig. 9).

Another interesting observation from our NGS analysis of cortical samples from the UUO study is the reduced expression of urea-transport associate genes in response to BI 685509 treatment. The *Slc14a2* gene (UT-A) encodes six isoforms of urea transporters. A recent study in UT-A1/A3 knockout mice reported a reduced renal fibrotic response to UUO with a similar effect

noted with urea transporter pharmacologic inhibition (Rianto et al., 2020). Thus, it is plausible that the reduced expression of urea transporters (Slc14a1, Slc14a2, Upk3a, and Aqp3) with BI 685509 treatment could also contribute to the reduction in fibrosis observed in this study.

Additionally, although it is not anticipated that sGC activators would directly affect podocytes in the UUO model, we report evidence of reduced podocytopathy as a potential secondary effect since podocyte-associated genes including *Nphs1*, *Nphs2*, and *Podxl* for which expression is decreased in vehicle-treated UUO group are partially preserved with BI 685509 treatment (Suppl. Fig. 8) concomitant with reductions in TIF. Given that recent studies have demonstrated that acute and repeated tubular-specific renal injury is able to elicit the full spectrum of renal fibrosis including glomerulosclerosis (Grgic et al., 2012; Takori et al., 2016), the concept of reduced podocytopathy in the UUO model in association with BI 685509-induced inhibition of TIF has merit and underscores the potential clinical benefit of the anti-fibrotic effects of sGC activators in patients with kidney disease.

In summary, BI 685509 is a potent and orally bioavailable sGC activator with clear disease modifying potential. The ability of BI 685509 to reduce proteinuria and glomerular sclerosis dose dependently when co-administered on top of enalapril in a preclinical model of DKD, combined with a reduced TIF in the rat UUO model give credence to its therapeutic potential and provides strong rationale for continued Phase II clinical development in patients with CKD/DKD.

## Acknowledgements

None

## Authorship Contributions

*Participated in research design:* Harrison, Sun, Wong, Fryer, Brenneman, Sarko, Boustany-Kari, and Pullen.

*Conducted experiments:* Harrison, Lincoln, Chen, Sun, Clifford, Ng, Wang, Fowler, Gueneva-Boucheva, and Zhang.

*Contributed new reagents:* Brenneman, Bosanac, and Sarko.

*Performed data analysis:* Harrison, Lincoln, Sun, Qian, McHugh, Wang, Fowler, Gueneva-Boucheva, Wong, Fryer, and Hill

*Wrote or contributed to writing of the manuscript:* Harrison, Ng, Hill, Wong, Fryer, Boustany-Kari, Reinhart and Pullen.

## References

- An Y, Xu F, Le W, Ge Y, Zhou M, Chen H, Zeng C, Zhang H and Liu Z (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. *Nephrol Dial Transplant* **30** (2): 257-266.
- Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, Wong D, Fryer RM, Richman JG, Sarko C and SS Pullen (2016) A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat. *J Pharmacol Exp Ther* **356** (3) 712-719.
- Bénardeau A, Kahnert A, Schomber T, Meyer J, Pavkovic M, Kretschmer A, Lawrenz B, Hartmann E, Mathar I, Hueser J, Kraehling JR, Eitner F, Hahn MG, Stasch JP and P Sandner P (2021). Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. *Naunyn Schmiedebergs Arch Pharmacol.* **394** (12):2363-2379.
- Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. *NE J Med* **345** (12): 861-869.
- Centers for Disease Control and Prevention. *National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014* (2014) Atlanta, GA, U.S. Department of Health and Human Services.

Dellamea BS, Ferreira Pinto LC, Leitao CB, Santos KG and Santos Canani LH (2014)

Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systemic review and meta-analysis. *BMC Medical Genetics* **15** (9): 1-13.

Fryer, Ryan M Harrison PC, Muthukumarana A, Nodop Mazurek SG, Ng KJ, Chen RR, Harrington KE, Dinallo RM, Chi L and GA Reinhart GA (2012). “Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.” *J Cardiovascular Pharmacology* **59** (4): 369-376.

Gewin LS (2018) Renal Fibrosis: Primacy of the Proximal Tubule *Matrix Biol.* 68-69: 248–262.

Gillis EE, Brinson KN, Rafikova O, Chen W, Musall JB, Harrison DG, and JC Sullivan (2018), Oxidative stress induces BH<sub>4</sub> deficiency in male, but not female, SHR. *Biosci Rep.* 38(4).

Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura T, Humphreys BD, and JV Bonventre (2012). Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. *Kidney Int* (**82**), 172-183.

Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den

Akker F, Schaefer M, Geiss V, Sandner P and JP Stasch (2021). Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). *J Med Chem.* **13** 64(9):5323-5344.

Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A and Iwamoto Y (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. *Nephrol Dial Transplant* **24**: 1884-1888.

Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving H-H and Rossing P (2008) Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in Type-1 diabetic patients with diabetic nephropathy. *Diabetes Care* **31** (4): 747-752.

Lewis EJ, Hunsicker LG, Bain RP and Rhode RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *NE J Med* **329** (20): 1456-1462.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rhode R and Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. *NE J Med* **345** (12): 851-860.

Nagle RB, Bulger RE, Cutler RE, Jervis HR, Benditt EP. (1973) Unilateral obstructive nephropathy in the rabbit. I. Early morphologic, physiologic, and histochemical changes. *Lab Invest.* **28**(4):456-67.

Nedvetsky PI, Christoph Kleinschnitz C, and HHHW Schmidt (2002) Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation. *Brain Res.* (950);148-154.

Persson F, Rossing P, Hovind P, Stehouwer CDA, Schalkwijk CG, Tarnow L and Parving H-H (2008) Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the irbesartan in patients with Type 2 diabetes and microalbuminuria (IRMA) study. *The Scandinavian J Clin Lab Invest* 68 (8): 731-738.

Sembach FE., Østergaard MV, Vrang N, Feldt-Rasmussen B, Fosgerau K, Jelsing J, and LN Fink (2021). Rodent models of diabetic kidney disease: human translatability and preclinical validity. *Drug Disc Today* 26(1) 200-217.

Stasch J-P, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Pezborn E, Pleiß U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A and Schramm M (2001) NO-independent regulatory site on soluble guanylate cyclase. *Nature* 410: 212-215.

Stasch J-P, Dembowsky K, Perzborn E, Stahl E and Schramm M (2002) Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: *in vivo* studies. *British Journal of Pharmacology* 135: 344-355.

Stasch J-P, Schmidt PM, Nedvetsky P, Nedvetskaya TY, Kumar A, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl and W Schmidt HHHW (2006) Targeting the heme-oxidized nitric oxide



receptor for selective vasodilatation of diseased blood vessels. *J Clin Invest* **116** (9): 2552-2561.

Stasch J-P, Schlossmann J and Hocher B (2015) Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. *Current Opinion in Pharmacol* **21**: 95-104.

Takaori K, Nakamura J, Yamamoto S, Nakata H, Sato Y, Takase M, Nameta M, Yamamoto T, Economides AN, Kohno K, Haga H, Sharma K, and Motoko Yanagita (2016) Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis. *JASN* **27**:2393-2406.

Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im J G-Y, Sheppeck, J, II, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, and JL Masferrer (2018). Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. *J Pharmacol Exp Ther* **354**:664-664.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narvar AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT and Molitch ME (2014) Diabetic Kidney Disease: A Report From an ADA Consensus Conference. *Diabetes Care* **37**:2864-2883.

## Footnotes

This work received no external funding.

All authors were employed at Boehringer Ingelheim Pharmaceuticals at the time the research was performed. No author has an actual or perceived conflict of interest with the contents of this article.

## Figure Legends

**Fig. 1.** Structure of BI 685509.

**Fig.2.** A) Concentration-dependent effect of sGC activator BI 685509 and B) the sGC stimulator pralicyguat on cGMP generation from human sGC  $\alpha 1\beta 1$  heterodimer containing a reduced heme group (Reduced sGC) or no heme group (Heme-free sGC) in the presence and absence of NO.

**Fig. 3.** Concentration dependent effect of BI 685509 on cGMP levels in human platelet-rich plasma (PRP) from four volunteers treated with the heme-oxidant ODQ, yielding an average  $EC_{50}$  of 467 nM.

**Fig. 4.** Effect of sGC activation by BI 685509 on conscious A) MAP and B) HR after a single-oral dose in telemetry-instrumented rats following a 24-hr baseline period. Open downward triangles denote  $p < 0.05$  vs. vehicle. C) Daily effect of oral administration BI 685509 at suprathreshold doses ( $n = 12/\text{group}$ ) on conscious MAP and HR during a 10 day repeated treatment followed by a single oral challenge of BI 685509 at 100 mg/kg on the final day to assess attenuation of responses. Mean values for each group were compared each day by one-way ANOVA with Dunnett's post-test vs. vehicle without adjusting for repeated measures ( $p < 0.05$ ) as indicated by asterisk.

**Fig. 5.** Effect of sGC activation on MAP, HR, and UPE: A) Weekly MAP in ZSF1 rats. Lower doses of BI 685509, in combination with enalapril, showed significant reductions in MAP at 30,

10, 3 and 1 mg/kg beginning on weeks 2, 3, and 4, respectively, compared to vehicle, and beginning on week 2 at 10 mg/kg compared to enalapril alone. Enalapril at 3 mg/kg elicited significant reductions in MAP at weeks 7-10 compared to vehicle. B) Weekly HR in ZSF1. BI 685509 at 30 and 10 mg/kg, in combination with enalapril (3 mg/kg), resulted in significantly higher HR beginning on weeks 1 and 9 compared to enalapril alone. C) Weekly UPE in ZSF1 rats. BI 685509 at 30 and 10 mg/kg, in combination with enalapril (3 mg/kg,) significantly reduced UPE levels from weeks 4 and 8 onwards, respectively vs enalapril alone. BI 685509, in combination with enalapril, showed significant reductions in UPE at 30, 10, 3 and 1 mg/kg beginning on weeks 3, 3, 3 and 7 compared to vehicle. \* and # signifies statistical significance compared to vehicle and enalapril, respectively ( $p < 0.05$ , 2-way ANOVA with repeated measures and Bonferroni post-hoc analysis).

**Fig. 6.** Correlation of BI 685509 plasma exposure with UPE. A) Individual mean  $C_{max}$  (nM) vs. mean UPE and (B) individual mean AUC (nM\*hr) vs. mean UPE. Using a simple inhibitory effect  $I_{max}$  model, BI 685509 individual mean plasma concentrations from weeks 1, 4, 7 and 10 were correlated with the mean UPE levels (mg/day) from baseline for individual animals. Decreasing UPE levels correlated with increasing BI 685509 plasma exposure. An  $IC_{50}$  of 213 nM  $C_{max}$  (63.4% CV) and 1210 nM\*hr (63.5% CV) AUC was predicted to reduce UPE by 50% on top of enalapril.

**Fig. 7.** Effect of sGC activation in combination with enalapril on glomerular lesions. Representative glomerulosclerosis from (A) vehicle, (B) enalapril at 3 mg/kg, and (C-F) BI 685509 at 1, 3, 10 and 30 mg/kg in combination with enalapril at 3 mg/kg, respectively. Red

arrows indicate areas of advanced glomerular sclerosis in the vehicle control tissue. Based on semiquantitative glomerular scoring of 25 random glomeruli (1+, showing segmental condensation and structural collapse of approximately one quarter of the glomerular area; 2+, showing segmental condensation and structural collapse of half of the glomerular area; and 3+ showing condensation and structural collapse of most of the glomerular area), BI 685509 dose-dependently reduced glomerulosclerosis compared to enalapril alone.

**Fig. 8.** Effect of sGC activation on incidence of glomerulosclerosis. BI 685509 in combination with enalapril (3 mg/kg) dose-dependently reduced the incidence of glomerulosclerosis (glomerulosclerosis %) and showed statistically significant reductions at 10 and 30 mg/kg compared to enalapril alone and vehicle. \* and # signifies statistical significance compared to vehicle and enalapril (3 mg/kg), respectively ( $p < 0.05$ , 1-way ANOVA with Tukey's post-hoc analysis).

**Fig. 9.** Anti-fibrotic effect of sGC activation in 7-day rat UUO. BI 685509 reduced area of cortical tubulointerstitial fibrosis expressed as % of cortical area in sections stained with Sirius Red and subjected to quantitative morphometry. (\*\* $p < 0.01$  vs. Vehicle, \*  $p < 0.05$  vs. vehicle).

**Fig. 10A.** Principal component plot of samples from RNAseq experiment.

**Fig. 10B.** Heatmap of gene expression values from genes selected for sGC-induced signature across doses, based on a false discovery rate threshold of  $< 0.05$  and a threshold of  $\pm 2$ -fold change between groups.



## Tables

**Table 1. Effect of sGC activation on tissue markers of renal damage**

Treatment	$\alpha$ -SMA		KIM-1		ED-1	
	% Positive expression	Percent Change	% Positive expression	Percent Change	% Positive expression	Percent Change
Vehicle	6.40 $\pm$ 0.58		2.85 $\pm$ 0.43		1.89 $\pm$ 0.16	
Enalapril, 3 mg/kg	4.86 $\pm$ 0.45	-24.1*	2.42 $\pm$ 0.28	-15.4	1.79 $\pm$ 0.21	-5.3
BI 685509, 1 mg/kg + Enalapril, 3 mg/kg	4.14 $\pm$ 0.35	-35.4*	2.94 $\pm$ 0.34	3.1	1.92 $\pm$ 0.19	2.0
BI 685509, 3 mg/kg + Enalapril, 3 mg/kg	1.94 $\pm$ 0.17	-69.8* <sup>#</sup>	1.54 $\pm$ 0.29	-45.9*	1.14 $\pm$ 0.25	-39.5
BI 685509, 10 mg/kg + Enalapril, 3 mg/kg	2.54 $\pm$ 0.22	-60.4* <sup>#</sup>	1.33 $\pm$ 0.17	-53.3*	1.24 $\pm$ 0.16	-34.3
BI 685509, 30 mg/kg + Enalapril, 3 mg/kg	2.89 $\pm$ 0.39	-54.9* <sup>#</sup>	1.58 $\pm$ 0.31	-44.6	1.09 $\pm$ 0.19	-42.3

Tissue markers of renal damage,  $\alpha$ -SMA, KIM-1 and ED-1, were quantified by immunohistochemistry and expressed as mean  $\pm$  SEM percent positive expression area/glomeruli and as a percent change from vehicle control. \*and <sup>#</sup> significant p<0.05 vs vehicle and enalapril, respectively using 1-way ANOVA.

# Fig. 1






Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6





Fig. 7









Fig. 8




Fig. 9






Fig. 10

